Total Payments
$37,517
2024 Payments
$2,332
Companies
62
Transactions
1,007
Medicare Patients
4,140
Medicare Billing
$453,442
Payment Breakdown by Category
Research$18,603 (49.6%)
Food & Beverage$12,575 (33.5%)
Consulting$6,175 (16.5%)
Education$164.39 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,603 | 5 | 49.6% |
| Food and Beverage | $12,575 | 975 | 33.5% |
| Consulting Fee | $6,175 | 5 | 16.5% |
| Education | $164.39 | 22 | 0.4% |
Payments by Type
General
$18,914
1,002 transactions
Research
$18,603
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $25,392 | 93 | $0 (2024) |
| ABBVIE INC. | $1,295 | 116 | $0 (2024) |
| Amgen Inc. | $1,245 | 86 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $880.80 | 40 | $0 (2024) |
| GlaxoSmithKline, LLC. | $872.02 | 66 | $0 (2024) |
| Novo Nordisk Inc | $821.94 | 65 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $643.42 | 48 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $556.92 | 56 | $0 (2024) |
| Lilly USA, LLC | $450.22 | 37 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $432.67 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,332 | 152 | ABBVIE INC. ($302.81) |
| 2023 | $22,333 | 132 | PFIZER INC. ($20,650) |
| 2022 | $2,167 | 154 | Amgen Inc. ($253.23) |
| 2021 | $6,390 | 169 | PFIZER INC. ($4,267) |
| 2020 | $14.25 | 1 | MERZ NORTH AMERICA, INC. ($14.25) |
| 2019 | $872.96 | 64 | Merz North America, Inc. ($247.96) |
| 2018 | $1,733 | 161 | AstraZeneca Pharmaceuticals LP ($229.51) |
| 2017 | $1,676 | 174 | Boehringer Ingelheim Pharmaceuticals, Inc. ($168.62) |
All Payment Transactions
1,007 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Diabetes | ||||||
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $9.49 | General |
| Category: Gastroenterology | ||||||
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $2.94 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: ANTI-ANXIETY | ||||||
| 12/12/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 12/10/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.40 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Kowa Pharmaceuticals America, Inc. | ZORYVE (Drug) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: DERMATOLOGY | ||||||
| 11/11/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: PSYCHIATRY | ||||||
| 11/04/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Inflammation | ||||||
| 11/01/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: ANTI-ANXIETY | ||||||
| 10/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/24/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Inflammation | ||||||
| 10/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Cardio-renal | ||||||
| 10/17/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $7.38 | General |
| Category: ANTI-ANXIETY | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $13,801 | 3 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $4,802 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,289 | 4,848 | $331,221 | $164,754 |
| 2022 | 28 | 1,435 | 4,545 | $344,080 | $173,013 |
| 2021 | 14 | 667 | 1,471 | $143,692 | $67,800 |
| 2020 | 19 | 749 | 1,071 | $117,304 | $47,875 |
Total Patients
4,140
Total Services
11,935
Medicare Billing
$453,442
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 188 | 408 | $73,848 | $33,287 | 45.1% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 56 | 892 | $53,520 | $25,549 | 47.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 61 | 525 | $39,375 | $23,366 | 59.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 60 | 560 | $36,400 | $19,119 | 52.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 59 | 539 | $32,340 | $18,665 | 57.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 132 | 263 | $32,875 | $14,762 | 44.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 69 | 69 | $11,385 | $8,288 | 72.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 50 | 118 | $7,670 | $3,688 | 48.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 182 | 365 | $3,650 | $3,042 | 83.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 63 | 69 | $5,175 | $2,253 | 43.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 24 | 27 | $4,239 | $2,044 | 48.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 25 | 34 | $3,570 | $1,451 | 40.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 54 | 150 | $4,500 | $1,411 | 31.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $3,549 | $1,329 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $2,684 | $1,328 | 49.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 25 | 36 | $3,348 | $1,288 | 38.5% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 12 | 12 | $1,980 | $1,117 | 56.4% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 12 | 12 | $1,260 | $713.28 | 56.6% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 11 | 14 | $1,274 | $518.86 | 40.7% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 12 | 14 | $1,050 | $418.56 | 39.9% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 17 | 23 | $506.00 | $315.79 | 62.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 14 | 14 | $420.00 | $238.28 | 56.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 46 | 281 | $2,810 | $198.45 | 7.1% |
| 81002 | Urinalysis, manual test | Office | 2023 | 36 | 49 | $257.25 | $167.09 | 65.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 44 | 332 | $3,320 | $118.76 | 3.6% |
About Dr. Hubert Reyes, MD
Dr. Hubert Reyes, MD is a Family Medicine healthcare provider based in Evansville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1497957526.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hubert Reyes, MD has received a total of $37,517 in payments from pharmaceutical and medical device companies, with $2,332 received in 2024. These payments were reported across 1,007 transactions from 62 companies. The most common payment nature is "" ($18,603).
As a Medicare-enrolled provider, Reyes has provided services to 4,140 Medicare beneficiaries, totaling 11,935 services with total Medicare billing of $453,442. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Evansville, IN
- Active Since 06/01/2007
- Last Updated 06/29/2021
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1497957526
Products in Payments
- ZAVZPRET (Drug) $13,801
- NURTEC ODT (Drug) $4,947
- FARXIGA (Drug) $736.35
- XIFAXAN (Drug) $643.42
- VRAYLAR (Drug) $629.09
- Otezla (Drug) $539.06
- TRELEGY ELLIPTA (Drug) $526.96
- XARELTO (Drug) $485.96
- UBRELVY (Drug) $425.46
- REXULTI (Drug) $393.61
- JARDIANCE (Drug) $298.17
- Ozempic (Drug) $277.84
- ELIQUIS (Drug) $274.91
- EVENITY (Biological) $251.96
- Auvelity (Drug) $251.22
- XEOMIN (Biological) $247.96
- Vascepa (Drug) $226.62
- LEQVIO (Drug) $220.01
- LINZESS (Drug) $209.47
- Aimovig (Biological) $201.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Evansville
David Schultz, M.d, M.D
Family Medicine — Payments: $756,324
Family Medicine $756,324
J Sartore, Md, MD
Family Medicine — Payments: $425,777
Family Medicine $425,777
Dr. Anthony Inzerello, M.d, M.D
Family Medicine — Payments: $315,157
Family Medicine $315,157
Carol Goodman, Md, MD
Family Medicine — Payments: $125,655
Family Medicine $125,655
Randall Oliver, M.d, M.D
Family Medicine — Payments: $75,540
Family Medicine $75,540
David Brougher, M.d, M.D
Family Medicine — Payments: $62,934
Family Medicine $62,934